An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice

Journal of Virology

Volumn 88, Issue 16, 2014, Pages 9182-9196

  Khalil, Syed Muaz ^a,b   Tonkin, Daniel R ^a   Snead, Andrew T ^a   Parks, Griffith D ^c   Johnston, Robert E ^a   White, Laura J ^a  

^a Global Vaccines Inc   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; INFLUENZA VACCINE; INTERLEUKIN 6; RNA; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; INFLUENZA; INFLUENZA VIRUS; INNATE IMMUNITY; LYMPH NODE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RNA REPLICATION; RNA SYNTHESIS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ALPHAVIRUS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, VIRAL; ANTIBODY FORMATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CERCOPITHECUS AETHIOPS; CYTOKINES; DENDRITIC CELLS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; T-LYMPHOCYTES; VACCINATION; VACCINES, INACTIVATED; VERO CELLS;

EID: 84904881527     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00327-14     Document Type: Article

References (80)

1. World Health Organization. 2014. World health statistics. World Health Organization, Geneva, Switzerland. http://apps.who.int/iris/bitstream/10 665/112738/1/9789240692671_eng.pdf?ua1.
2. Adkins B, Leclerc C, Marshall-Clarke S. 2004. Neonatal adaptive immunity comes of age. Nat. Rev. Immunol. 4:553-564. http://dx.doi.org/10.1038/nri1394.
3. Zaghouani H, Hoeman CM, Adkins B. 2009. Neonatal immunity: faulty T-helpers and the shortcomings of dendritic cells. Trends Immunol. 30: 585-591. http://dx.doi.org/10.1016/j.it.2009.09.002.
4. Langrish CL, Buddle JC, Thrasher AJ, Goldblatt D. 2002. Neonatal dendritic cells are intrinsically biased against Th-1 immune responses. Clin. Exp. Immunol. 128:118-123. http://dx.doi.org/10.1046/j.1365-2249.2002.01817.x.
5. Siegrist CA. 2001. Neonatal and early life vaccinology. Vaccine 19:3331-3346. http://dx.doi.org/10.1016/S0264-410X(01)00028-7.
6. Willems F, Vollstedt S, Suter M. 2009. Phenotype and function of neonatal DC. Eur. J. Immunol. 39:26-35. http://dx.doi.org/10.1002/eji.200838391.
7. de Brito CA, Goldoni AL, Sato MN. 2009. Immune adjuvants in early life: targeting the innateimmunesystem to overcome impaired adaptive response. Immunotherapy 1:883-895. http://dx.doi.org/10.2217/imt.09.38.
8. Futata EA, Fusaro AE, de Brito CA, Sato MN. 2012. The neonatal immune system: immunomodulation of infections in early life. Expert Rev. Anti Infect. Ther. 10:289-298. http://dx.doi.org/10.1586/eri.12.9.
9. PrabhuDas M, Adkins B, Gans H, King C, Levy O, Ramilo O, Siegrist CA. 2011. Challenges in infant immunity: implications for responses to infection and vaccines. Nat. Immunol. 12:189-194. http://dx.doi.org/10.1038/ni0311-189.
10. Prendergast AJ, Klenerman P, Goulder PJ. 2012. The impact of differential antiviral immunity in children and adults. Nat. Rev. Immunol. 12: 636-648. http://dx.doi.org/10.1038/nri3277.
11. Centers for Disease Control and Prevention. 2010. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morb. Mortal. Wkly. Rep. 59:1057-1062. http://www.cdc.gov/mmwr/pdf/wk/mm5933.pdf.
12. Barnard DL. 2009. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res. 82:A110-A122. http://dx.doi.org/10.1016/j.antiviral.2008.12.014.
13. Stamboulian D, Bonvehi PE, Nacinovich FM, Cox N. 2000.Influenza. Infect. Dis. Clin. North Am. 14:141-166. http://dx.doi.org/10.1016/S0891-5520(05)70222-1.
14. Kohlmeier JE, Woodland DL. 2009. Immunity to respiratory viruses. Annu. Rev. Immunol. 27:61-82. http://dx.doi.org/10.1146/annurev.immunol.021908.132625.
15. Labella AM, Merel SE. 2013. Influenza. Med. Clin. North Am. 97:621-645. http://dx.doi.org/10.1016/j.mcna.2013.03.001.
16. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM, CAIV-T Comparative Efficacy Study Group. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356:685-696. http://dx.doi.org/10.1056/NEJMoa065368.
17. Zangwill KM, Belshe RB. 2004. Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr. Infect. Dis. J. 23:189-197. http://dx.doi.org/10.1097/01.inf.0000116292.46143.d6.
18. Marchant A, Goetghebuer T, Ota MO, Wolfe I, Ceesay SJ, De Groote D, Corrah T, Bennett S, Wheeler J, Huygen K, Aaby P, McAdam KP, Newport MJ. 1999. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guerin vaccination. J. Immunol. 163:2249-2255.
19. Wu CY, Demeure C, Kiniwa M, Gately M, Delespesse G. 1993. IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J. Immunol. 151:1938-1949.
20. Dowling DJ, Tan Z, Prokopowicz ZM, Palmer CD, Matthews MA, Dietsch GN, Hershberg RM, Levy O. 2013. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 8:e58164. http://dx.doi.org/10.1371/journal.pone.0058164.
21. Levy O, Suter EE, Miller RL, Wessels MR. 2006. Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigenpresenting cells. Blood 108:1284-1290. http://dx.doi.org/10.1182/blood-2005-12-4821.
22. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, Krieg AM, Siegrist CA. 1999. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J. Immunol. 162:1611-1617.
23. Olafsdottir TA, Lingnau K, Nagy E, Jonsdottir I. 2009. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice. Scand. J. Immunol. 69:194-202. http://dx.doi.org/10.1111/j.1365-3083.2008.02225.x.
24. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA. 1996. Partial correction of the TH2/TH1 imbalance in neonatal murine responses to vaccine antigens through selective adjuvant effects. Eur. J. Immunol. 26: 2666-2670. http://dx.doi.org/10.1002/eji.1830261118.
25. Forsthuber T, Yip HC, Lehmann PV. 1996. Induction of TH1 and TH2 immunity in neonatal mice. Science 271:1728-1730. http://dx.doi.org/10.1126/science.271.5256.1728.
26. Kenney RT, Edelman R. 2003. Survey of human-use adjuvants. Expert Rev. Vaccines 2:167-188. http://dx.doi.org/10.1586/14760584.2.2.167.
27. Craig CP, Reynolds SL, Airhart JW, Staab EV. 1969. Alterations in immune responses by attenuated Venezuelan equine encephalitis vaccine. I. Adjuvant effect of VEE virus infection in guinea pigs. J. Immunol. 102: 1220-1227.
28. Howard RJ, Craig CP, Trevino GS, Dougherty SF, Mergenhagen SE. 1969. Enhanced humoral immunity in mice infected with attenuated Venezuelan equine encephalitis virus. J. Immunol. 103:699-707.
29. Thompson JM, Whitmore AC, Konopka JL, Collier ML, Richmond EM, Davis NL, Staats HF, Johnston RE. 2006. Mucosal and systemic adjuvant activity of alphavirus replicon particles. Proc. Natl. Acad. Sci. U. S. A. 103:3722-3727. http://dx.doi.org/10.1073/pnas.0600287103.
30. Hidmark AS, Nordstrom EK, Dosenovic P, Forsell MN, Liljestrom P, Karlsson Hedestam GB. 2006. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/ beta interferon signaling. J. Virol. 80:7100-7110. http://dx.doi.org/10.1128/JVI.02579-05.
31. Tonkin DR, Jorquera P, Todd T, Beard CW, Johnston RE, Barro M. 2010. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization. Vaccine 28:3238-3246. http://dx.doi.org/10.1016/j.vaccine.2010.02.010.
32. Steil BP, Jorquera P, Westdijk J, Bakker WA, Johnston RE, Barro M. 2014. A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine 32:558-563. http://dx.doi.org/10.1016/j.vaccine.2013.11.101.
33. LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. 2009. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J. Virol. 83:3212-3227. http://dx.doi.org/10.1128/JVI.01650-08.
34. Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, Miller CJ, Johnston RE. 2011. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone in rhesus macaques. Vaccine 29:931-940. http://dx.doi.org/10.1016/j.vaccine.2010.11.024.
35. White LJ, Sariol CA, Mattocks MD, Wahala MPBW, Yingsiwaphat V, Collier ML, Whitley J, Mikkelsen R, Rodriguez IV, Martinez MI, de Silva A, Johnston RE. 2013. An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection. J. Virol. 87:3409-3424. http://dx.doi.org/10.1128/JVI.02298-12.
36. MacDonald GH, Johnston RE. 2000. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74:914-922. http://dx.doi.org/10.1128/JVI.74.2.914-922.2000.
37. Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM, Johnston RE, Serody JS. 2007. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 25:6604-6612. http://dx.doi.org/10.1016/j.vaccine.2007.06.058.
38. Moran TP, Collier M, McKinnon KP, Davis NL, Johnston RE, Serody JS. 2005. A novel viral system for generating antigen-specific T cells. J. Immunol. 175:3431-3438. http://dx.doi.org/10.4049/jimmunol.175.5.3431.
39. Nishimoto KP, Laust AK, Wang K, Kamrud KI, Hubby B, Smith JF, Nelson EL. 2007. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells. Viral Immunol. 20:88-104. http://dx.doi.org/10.1089/vim.2006.0090.
40. Tonkin DR, Whitmore A, Johnston RE, Barro M. 2012. Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine 30:4532-4542. http://dx.doi.org/10.1016/j.vaccine.2012.04.030.
41. Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, Connell MJ, Montefiori DC, Frelinger JA, Swanstrom R, Johnson PR, Johnston RE. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74:371-378. http://dx.doi.org/10.1128/JVI.74.1.371-378.2000.
42. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239:389-401. http://dx.doi.org/10.1006/viro.1997.8878.
43. Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF, Johnston RE. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183:20-31. http://dx.doi.org/10.1016/0042-6822(91)90114-Q.
44. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
45. Davis NL, Brown KW, Johnston RE. 1996. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70:3781-3787.
46. Thompson JM, Nicholson MG, Whitmore AC, Zamora M, West A, Iwasaki A, Staats HF, Johnston RE. 2008. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node. J. Immunol. 181:574-585. http://dx.doi.org/10.4049/jimmunol.181.1.574.
47. Schafer A, Brooke CB, Whitmore AC, Johnston RE. 2011. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection. J. Virol. 85:10682-10690. http://dx.doi.org/10.1128/JVI.05032-11.
48. Cottey R, Rowe CA, Bender BS. 2001. Influenza virus. Curr. Protoc. Immunol. Chapter 19:Unit 19.11. http://dx.doi.org/10.1002/0471142735.im1911s42.
49. Cruz CC, Suthar MS, Montgomery SA, Shabman R, Simmons J, Johnston RE, Morrison TE, Heise MT. 2010. Modulation of type I IFN induction by a virulence determinant within the alphavirus nsP1 protein. Virology 399:1-10. http://dx.doi.org/10.1016/j.virol.2009.12.031.
50. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
51. Thompson JM, Whitmore AC, Staats HF, Johnston R. 2008. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines. Vaccine 26:4998-5003. http://dx.doi.org/10.1016/j.vaccine.2008.07.011.
52. Thompson JM, Whitmore AC, Staats HF, Johnston RE. 2008. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen. Vaccine 26:4267-4275. http://dx.doi.org/10.1016/j.vaccine.2008.05.046.
53. Holmgren J, Czerkinsky C. 2005. Mucosal immunity and vaccines. Nat. Med. 11(Suppl 4):S45-S53. http://dx.doi.org/10.1038/nm1213.
54. Mestecky J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7:265-276. http://dx.doi.org/10.1007/BF00915547.
55. Elson CO, Ealding W, Lefkowitz J. 1984. A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J. Immunol.Methods67:101-108.http://dx.doi.org/10.1016/0022-1759(84) 90089-9.
56. Stetson DB, Medzhitov R. 2006. Type I interferons in host defense. Immunity 25:373-381. http://dx.doi.org/10.1016/j.immuni.2006.08.007.
57. Adkins B, Bu Y, Guevara P. 2002. Murine neonatal CD4+ lymph node cells are highly deficient in the development of antigen-specific Th1 function in adoptive adult hosts. J. Immunol. 169:4998-5004. http://dx.doi.org/10.4049/jimmunol.169.9.4998.
58. Li L, Lee HH, Bell JJ, Gregg RK, Ellis JS, Gessner A, Zaghouani H. 2004. IL-4 utilizes an alternative receptor to drive apoptosis of Th1 cells and skews neonatal immunity toward Th2. Immunity 20:429-440. http://dx.doi.org/10.1016/S1074-7613(04)00072-X.
59. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SG. 1998. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J. Pediatr. 132:983-988. http://dx.doi.org/10.1016/S0022-3476(98)70395-6.
60. Tiru M, Hallander HO, Gustafsson L, Storsaeter J, Olin P. 2000. Diphtheria antitoxin response to DTP vaccines used in Swedish pertussis vaccine trials, persistence and projection for timing of booster. Vaccine 18:2295-2306. http://dx.doi.org/10.1016/S0264-410X(99)00539-3.
61. Pihlgren M, Friedli M, Tougne C, Rochat AF, Lambert PH, Siegrist CA. 2006. Reduced ability of neonatal and early-life bone marrow stromal cells to support plasmablast survival. J. Immunol. 176:165-172. http://dx.doi.org/10.4049/jimmunol.176.1.165.
62. Pihlgren M, Schallert N, Tougne C, Bozzotti P, Kovarik J, Fulurija A, Kosco-Vilbois M, Lambert PH, Siegrist CA. 2001. Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. Eur. J. Immunol. 31:939-946. http://dx.doi.org/10.1002/1521-4141 (200103)31:3<939::AID-IMMU939>3.0.CO;2-I.
63. Marshall-Clarke S, Tasker L, Parkhouse RM. 2000. Immature B lymphocytes from adult bone marrow exhibit a selective defect in induced hyperexpression of major histocompatibility complex class II and fail to show B7.2 induction. Immunology 100:141-151. http://dx.doi.org/10.1046/j.1365-2567.2000.00035.x.
64. Adkins B. 1999. T-cell function in newborn mice and humans. Immunol. Today 20:330-335. http://dx.doi.org/10.1016/S0167-5699(99)01473-5.
65. Kovarik J, Siegrist CA. 1998. Optimization of vaccine responses in early life: the role of delivery systems and immunomodulators. Immunol. Cell Biol. 76:222-236. http://dx.doi.org/10.1046/j.1440-1711.1998.00746.x.
66. Siegrist CA. 2007. The challenges of vaccine responses in early life: selected examples. J. Comp. Pathol. 137(Suppl 1):S4-S9.
67. Grewal HM, Karlsen TH, Vetvik H, Ahren C, Gjessing HK, Sommerfelt H, Haneberg B. 2000. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J. Immunol. Methods 239:53-62. http://dx.doi.org/10.1016/S0022-1759 (00)00171-X.
68. Chen J, Fang F, Li X, Chang H, Chen Z. 2005. Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine 23:4322-4328. http://dx.doi.org/10.1016/j.vaccine.2005.03.035.
69. Chen Z, Matsuo K, Asanuma H, Takahashi H, Iwasaki T, Suzuki Y, Aizawa C, Kurata T, Tamura S. 1999. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs. Vaccine 17:653-659. http://dx.doi.org/10.1016/S0264-410X(98)00247-3.
70. Galarza JM, Latham T, Cupo A. 2005. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 18:365-372. http://dx.doi.org/10.1089/vim.2005.18.365.
71. Dadaglio G, Sun CM, Lo-Man R, Siegrist CA, Leclerc C. 2002. Efficient in vivo priming of specific cytotoxic T cell responses by neonatal dendritic cells. J. Immunol. 168:2219-2224. http://dx.doi.org/10.4049/jimmunol.168.5.2219.
72. Dakic A, Shao QX, D'Amico A, O'Keeffe M, Chen WF, Shortman K, Wu L. 2004. Development of the dendritic cell system during mouse ontogeny. J. Immunol. 172:1018-1027. http://dx.doi.org/10.4049/jimmunol.172.2.1018.
73. Garcia AM, Fadel SA, Cao S, Sarzotti M. 2000. T cell immunity in neonates. Immunol. Res. 22:177-190. http://dx.doi.org/10.1385/IR:22:2-3:177.
74. Muthukkumar S, Goldstein J, Stein KE. 2000. The ability of B cells and dendritic cells to present antigen increases during ontogeny. J. Immunol. 165:4803-4813. http://dx.doi.org/10.4049/jimmunol.165.9.4803.
75. Sun CM, Fiette L, Tanguy M, Leclerc C, Lo-Man R. 2003. Ontogeny and innate properties of neonatal dendritic cells. Blood 102:585-591. http://dx.doi.org/10.1182/blood-2002-09-2966.
76. Aksoy E, Albarani V, Nguyen M, Laes JF, Ruelle JL, De Wit D, Willems F, Goldman M, Goriely S. 2007. Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood 109:2887-2893.
77. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, Willems F. 2004. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. Blood 103: 1030-1032.
78. Cusumano V, Mancuso G, Genovese F, Cuzzola M, Carbone M, Cook JA, Cochran JB, Teti G. 1997. Neonatal hypersusceptibility to endotoxin correlates with increased tumor necrosis factor production in mice. J. Infect. Dis. 176:168-176. http://dx.doi.org/10.1086/514019.
79. Vekemans J, Amedei A, Ota MO, D'Elios MM, Goetghebuer T, Ismaili J, Newport MJ, Del Prete G, Goldman M, McAdam KP, Marchant A. 2001. Neonatal bacillus Calmette-Guerin vaccination induces adult-like IFN-gamma production by CD4+ T lymphocytes. Eur. J. Immunol. 31:1531-1535.http://dx.doi.org/10.1002/1521-4141(200105)31:5+1531:: AID-IMMU1531 3.0.CO;2-1.
80. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168:3195-3204. http://dx.doi.org/10.4049/jimmunol.168.7.3195.